FAP-Targeted ADCs With Cleavable Linkers for Selective Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) targeting fibroblast activation protein (FAP) face challenges in achieving selective binding and efficient internalization, leading to potential drug resistance and reduced efficacy in cancer treatment.
Innovation Solution
Development of anti-FAP ADCs with specific CDR sequences and a protease-cleavable linker, conjugated with monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF), which exhibit selective binding to the extracellular region of FAP and efficient internalization, enhancing cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ADCs targeting FAP are used, then cancer treatment is provided, but selective binding and efficient internalization are not achieved, leading to drug resistance and reduced efficacy
Solution Approach 1:
The patent applies local quality by engineering specific CDR sequences (HC-CDR1: ENIIH, HC-CDR2: WFHPGSGSIKYNEKFKD, HC-CDR3: HGGTGRGAMDY, LC-CDR1: RASKSVSTSAYSYMH, LC-CDR2: LASNLES, LC-CDR3: QHSRELPYT) that are optimized for FAP binding affinity and internalization efficiency. This localized optimization of antibody binding regions enhances selective binding to FAP-expressing tumor cells while maintaining specificity, directly resolving the contradiction between reliability and device complexity.
Solution Approach 2:
The patent employs parameter changes by modifying the antibody sequence parameters (specific CDR amino acid sequences) and linker characteristics (protease-cleavable design) to optimize ADC performance. These parameter optimizations enable efficient internalization and cytotoxic payload release, improving efficacy without adding unnecessary complexity to the overall ADC structure.
2Productivity
If ADCs with high cytotoxicity are used, then tumor cells are killed effectively, but damage to healthy tissues increases
Solution Approach 1:
The patent applies segmentation by dividing the ADC into distinct functional components: a FAP-specific antibody fragment for targeted binding, a protease-cleavable linker for controlled payload release, and a cytotoxic payload (MMAE or MMAF) for tumor cell killing. This segmentation ensures that cytotoxicity is activated only after specific binding to FAP-expressing tumor cells and internalization, minimizing damage to healthy tissues while maintaining high productivity against cancer cells.
Solution Approach 2:
The patent uses a protease-cleavable linker as an intermediary between the antibody and cytotoxic payload. This intermediary remains intact during circulation and binding to healthy tissues but is cleaved by intracellular proteases after internalization into tumor cells, thereby activating cytotoxicity only at the target site and protecting healthy tissues from premature exposure to the cytotoxic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-FAP ADCs demonstrate surprising in vitro and in vivo efficacy, effectively targeting and killing cancer cells while minimizing damage to healthy tissues, with potential applications in treating various solid tumors.
Implementation Method 1
The primary mechanism of action of ADCs involves the specific binding of the monoclonal antibody component to target antigens on the surface of cancer cells
Implementation Method 2
Upon binding, the ADC is internalized by cancer cells, resulting in intracellular release of cytotoxic payload
Implementation Method 3
L is a protease-cleavable linker
Implementation Method 4
They exert their mechanism of action by binding to tubulin to inhibit its polymerization and prevent microtubule depolymerization. This results in the disruption of microtubules, leading to disassembly and cell cycle arrest
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to anti-FAP-targeted antibody-drug conjugates (ADCs), in particular anti-FAP antibody-drug conjugates having the formula A-(L-D)p, or a pharmaceutically acceptable salt or solvate thereof, wherein A is an anti-FAP antibody, L is a linker, D is a drug comprising a dolastatin and p is 1 to 10. Methods of using such conjugates in the treatment of cancer are also disclosed.